Luye Pharma Group Ltd.
Luye Pharma Group Ltd. (LYPHF) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
lyphf · pe ratio · data through Jun 9, 2026
Core PE Ratio Metrics
Trailing 12 months · TTMInsufficient PE history data (fewer than 3 valid fiscal years).
PE Ratio vs Peers
Drug Manufacturers - General · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Luye Pharma Group Ltd.You LYPHF | $1.6B | 10.58x | -69.9% | $0.15 |
 Adcock Ingram Holdings Limited AIHLF | $624M | 7.40x | -79.0% | $5.85 |
 Biotage AB (publ) BITGF | $1.2B | 46.23x | +31.4% | $3.55 |
 Biotest AG BTTAY | $943M | 66.05x | +87.8% | $0.35 |
 CompuGroup Medical SE & Co. KGaA CMPUY | $1.2B | 33.34x | -5.2% | $0.67 |
 CompuGroup Medical SE & Co. KGaA CMPVF | $1.7B | 52.49x | +49.2% | $0.55 |
 China Shineway Pharmaceutical Group Limited CSWYF | $816M | 5.56x | -84.2% | $1.26 |
Industry Average 6 peers with valid PE | — | 35.18x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Luye Pharma Group Ltd. (LYPHF) measures how much investors pay for each dollar of the company's trailing earnings. LYPHF's current PE ratio of 10.58x is calculated by dividing its stock price of $0.40 by its TTM earnings per share of $0.15.
Frequently asked questions
LYPHF pe ratio · 6 questionsLYPHF's current PE ratio is 10.58x as of 2026-06-09, based on a stock price of $0.40 and TTM EPS of $0.15. Data sourced from Financial Modeling Prep via LYPHF's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Luye Pharma Group Ltd. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09